Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Year range
1.
Int. arch. otorhinolaryngol. (Impr.) ; 22(4): 400-403, Oct.-Dec. 2018. tab
Article in English | LILACS | ID: biblio-975604

ABSTRACT

Abstract Introduction Otomycosis is a common problem in otolaryngology practice. However, we usually encounter some difficulties in its treatment because many patients show resistance to antifungal agents, and present high recurrence rate. Objectives To determine the fungal pathogens that cause otomycosis as well as their susceptibility to the commonly used antifungal agents. Additionally, to discover the main reasons for antifungal resistance. Methods We conducted an experimental descriptive study on 122 patients clinically diagnosed with otomycosis from April 2016 to April 2017. Aural discharge specimens were collected for direct microscopic examination and fungal culture. In vitro antifungal susceptibility testing was performed against the commonly used antifungal drugs. We tested the isolated fungi for their enzymatic activity. Results Positive fungal infection was found in 102 samples. The most common fungal pathogens were Aspergillus and Candida species, with Aspergillus niger being the predominant isolate (51%). The antifungal susceptibility testing showed that mold isolates had the highest sensitivity to voriconazole (93.48%), while the highest resistance was to fluconazole (100%). For yeast, the highest sensitivity was to nystatin (88.24%), followed by amphotericin B (82.35%), and the highest resistance was to terbinafine (100%), followed by Itraconazole (94.12%). Filamentous fungi expressed a high enzymatic ability, making them more virulent. Conclusion The Aspergillus and Candida species are the most common fungal isolates in otomycosis. Voriconazole and Nystatin are the medications of choice for the treatment of otomycosis in our community. The high virulence of fungal pathogens is owed to their high enzymatic activity. Empirical use of antifungals should be discouraged.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Drug Resistance, Fungal , Otomycosis/microbiology , Fungi/isolation & purification , Antifungal Agents/pharmacology , Aspergillus/isolation & purification , Aspergillus niger/isolation & purification , Yeasts/isolation & purification , Candida/isolation & purification , Microbial Sensitivity Tests , Amphotericin B/pharmacology , Epidemiology, Descriptive , Epidemiology, Experimental , Itraconazole/pharmacology , Voriconazole/pharmacology , /pharmacology
2.
Rev. salud pública ; 19(6): 800-805, nov.-dic. 2017. tab
Article in English | LILACS | ID: biblio-962074

ABSTRACT

ABSTRACT Objective The aim of the present study was to evaluate the antifungal susceptibilities of isolates of Fusarium to amphotericin B, itraconazole and voriconazole. Methods The susceptibility of 44 isolates of Fusarium was tested by the E-test methodology. Results All the isolates were resistant to itraconazole, and 89 % and 54,5 % were resistant to amphotericin B and voriconazole, respectively. Discussion The results confirm the high level of resistance reported, regardless of the species or the strain of Fusarium involved. The high MICs level observed are worrying and suggest that new drugs are needed.(AU)


RESUMEN Objetivo Evaluar la susceptibilidad antifúngica in vitro de aislamientos de Fusarium a los antimicóticos amfotericina B, itraconazol y voriconazol. Métodos La susceptibilidad de 44 aislamientos clínicos de Fusarium fue evaluada por el método de difusión en disco, E-test. Resultados Todos los aislamientos fueron resistentes al itraconazol, y 89 % y 54,5 % fueron resistentes a la amfotericina B y al voriconazol, respectivamente. Discusión Los resultados confirman el alto nivel de resistencia reportado, independiente de la especie o la cepa de Fusarium involucrada. Los valores tan altos de MICs son preocupantes y sugieren la necesidad de evaluar nuevos medicamentos.(AU)


Subject(s)
Itraconazole/pharmacology , Voriconazole/pharmacology , Fusarium/isolation & purification , Colombia , Disk Diffusion Antimicrobial Tests/instrumentation
3.
Rev. Soc. Bras. Med. Trop ; 50(6): 843-847, Nov.-Dec. 2017. tab
Article in English | LILACS | ID: biblio-1041438

ABSTRACT

Abstract INTRODUCTION Incidence and antifungal susceptibility of Candida spp. from two teaching public hospitals are described. METHODS The minimum inhibitory concentrations of fluconazole, voriconazole, itraconazole, and amphotericin B were determined using Clinical Laboratory Standard Institute broth microdilution and genomic differentiation using PCR. RESULTS Of 221 Candida isolates, 50.2% were obtained from intensive care unit patients; 71.5% were recovered from urine and 9.1% from bloodstream samples. Candida parapsilosis sensu stricto was the most common candidemia agent. CONCLUSIONS We observed variations in Candida species distribution in hospitals in the same geographic region and documented the emergence of non-C. albicans species resistant to azoles.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Adolescent , Adult , Young Adult , Candida/drug effects , Candidiasis/microbiology , Antifungal Agents/pharmacology , Brazil , Candida/classification , Candida/genetics , Microbial Sensitivity Tests , Fluconazole/pharmacology , Amphotericin B/pharmacology , Itraconazole/pharmacology , Drug Resistance, Fungal , Voriconazole/pharmacology , Hospitals, Public , Middle Aged
4.
Mem. Inst. Oswaldo Cruz ; 111(3): 192-199, Mar. 2016. tab, graf
Article in English | LILACS | ID: lil-777368

ABSTRACT

The azoles are the class of medications most commonly used to fight infections caused by Candida sp. Typically, resistance can be attributed to mutations in ERG11 gene (CYP51) which encodes the cytochrome P450 14α-demethylase, the primary target for the activity of azoles. The objective of this study was to identify mutations in the coding region of theERG11 gene in clinical isolates of Candidaspecies known to be resistant to azoles. We identified three new synonymous mutations in the ERG11 gene in the isolates of Candida glabrata (C108G, C423T and A1581G) and two new nonsynonymous mutations in the isolates of Candida krusei - A497C (Y166S) and G1570A (G524R). The functional consequence of these nonsynonymous mutations was predicted using evolutionary conservation scores. The G524R mutation did not have effect on 14α-demethylase functionality, while the Y166S mutation was found to affect the enzyme. This observation suggests a possible link between the mutation and dose-dependent sensitivity to voriconazole in the clinical isolate of C. krusei. Although the presence of the Y166S in phenotype of reduced azole sensitivity observed in isolate C. kruseidemands investigation, it might contribute to the search of new therapeutic agents against resistant Candida isolates.


Subject(s)
Humans , Candida/drug effects , Candida/genetics , Drug Resistance, Fungal/genetics , Point Mutation/drug effects , /genetics , Antifungal Agents/pharmacology , Azoles/pharmacology , Candida glabrata/genetics , Candida/classification , Candida/isolation & purification , Dose-Response Relationship, Drug , Genes, Fungal , Haplotypes/drug effects , Microbial Sensitivity Tests , Phylogeny , Voriconazole/pharmacology
5.
Rev. Inst. Med. Trop. Säo Paulo ; 57(4): 289-294, July-Aug. 2015. tab
Article in English | LILACS | ID: lil-761166

ABSTRACT

SUMMARYSporothrix schenckiiwas reclassified as a complex encompassing six cryptic species, which calls for the reassessment of clinical and epidemiological data of these new species. We evaluated the susceptibility of Sporothrix albicans(n = 1) , S. brasiliensis(n = 6) , S. globosa(n = 1), S. mexicana(n = 1) and S. schenckii(n = 36) to terbinafine (TRB) alone and in combination with itraconazole (ITZ), ketoconazole (KTZ), and voriconazole (VRZ) by a checkerboard microdilution method and determined the enzymatic profile of these species with the API-ZYM kit. Most interactions were additive (27.5%, 32.5% and 5%) or indifferent (70%, 50% and 52.5%) for TRB+KTZ, TRB+ITZ and TRB+VRZ, respectively. Antagonisms were observed in 42.5% of isolates for the TRB+VRZ combination. Based on enzymatic profiling, the Sporothrix schenckiistrains were categorized into 14 biotypes. Leucine arylamidase (LA) activity was observed only for S. albicansand S. mexicana. The species S. globosaand S. mexicanawere the only species without β-glucosidase (GS) activity. Our results may contribute to a better understanding of virulence and resistance among species of the genus Sporothrixin further studies.


RESUMOAvaliou-se a susceptibilidade de Sporothrix albicans(n = 1), S. brasiliensis(n = 1), S. globosa(n = 1), S. mexicana(n = 1) e S. schenckii(n = 36) frente à terbinafina (TRB) e a TRB em combinação com itraconazol (ITZ), cetoconazol (KTZ) e voriconazol (VRZ) pelo método de microdiluição ( checkerboard); o perfil enzimático destas espécies foi também avaliado, com base no kit API-ZYM. A maioria das interações foram aditivas (27,5%, 32,5% e 5%) ou indiferentes (70%, 50% e 52,5%) para TRB+KTZ, TRB+ITZ e TRB+VRZ, respectivamente. Antagonismo foi observado em 42,5% dos isolados para a combinação TRB+VRZ. Com base nos perfis enzimáticos, as cepas de Sporothrix schenckiievidenciaram 14 biotipos distintos. A atividade da leucina arilamidase (LA) só foi observada em S. albicanse S. mexicana.As espécies S. globosae S. mexicanaforam as únicas que não evidenciaram atividade da enzima β-glucosidase (GS). Estes resultados poderão contribuir para um melhor entendimento da virulência e resistência entre as espécies do gênero Sporothrixem futuros estudos.


Subject(s)
Humans , Animals , Cats , Antifungal Agents/pharmacology , Sporothrix/drug effects , Sporothrix/enzymology , Itraconazole/pharmacology , Ketoconazole/pharmacology , Microbial Sensitivity Tests , Naphthalenes/pharmacology , Phylogeny , Voriconazole/pharmacology
6.
Rev. chil. infectol ; 31(5): 511-517, oct. 2014. ilus, graf, tab
Article in Spanish | LILACS | ID: lil-730266

ABSTRACT

Introduction: The commensal yeast Candida albicans, can cause superficial or systemic candidiasis in susceptible hosts. In Chile, azole antifungals are the most widely used drugs in the treatment of candidiasis. In a previous study performed at our center, 2.1 and 1.6% of clinical isolates of C. albicans were found to be resistant to fluconazole and voriconazole, respectively. Objective: To characterize the resistance mechanisms involved in azoles resistance in Chilean clinical isolates. Methodology: Eight resistant, nine susceptible-dose dependent (SDD) and 10 susceptible strains (n: 27) were selected according to the Clinical Laboratory Standards Institute (CLSI) M27-S3 criteria, from vaginal and urine samples. Mutations in the 408-488 region of the ERG11 gene were studied by sequencing, and the relative expression of ERG11 gene and efflux pump genes CDR1, CDR2 and MDR1, was evaluated by quantitative real-time PCR (q-PCR). Results: No mutations were detected in the ERG11 gene and its overexpression was found only in 12.5% of the resistant strains (1/8). The most prevalent mechanism of resistance was the over-expression of efflux pumps (62.5%; 5/8). Conclusion: The study of the expression of efflux pumps by q-PCR could be a useful diagnostic tool for early detection of azole resistance in C. albicans.


Introducción: Candida albicans es una levadura comensal capaz de causar una infección oportunista en hospederos susceptibles denominada candidiasis, que puede ser superficial o sistémica. En Chile, los antifúngicos más utilizados para el tratamiento de las candidiasis son los azoles. En un estudio previo en nuestro centro, se detectó que 2,1 y 1,6% de cepas clínicas de C. albicans fueron resistentes a fluconazol y voriconazol, respectivamente. Objetivo: Caracterizar los mecanismos de resistencia involucrados en la resistencia a azoles en cepas clínicas chilenas. Metodología: Según los criterios del Clinical Laboratory Standards Institute (CLSI) M27-S3, se seleccionaron ocho cepas resistentes, nueve cepas susceptibles dosis dependiente (SDD) y 10 cepas sensibles (n: 27), aisladas de flujo vaginal y orina. Se evaluó la presencia de mutaciones en la región 408-488 del gen ERG11 por secuenciación y la expresión relativa del gen ERG11 y de los genes de bombas de eflujo CDR1, CDR2 y MDR1 por RPC en tiempo real cuantitativa (q-PCR). Resultados: No se encontraron mutaciones en el gen ERG11 y la sobre-expresión de éste sólo se presentó en 12,5% de las cepas resistentes (1/8). El mecanismo prevalente en la cepas resistentes fue la sobre-expresión de bombas de eflujo encontrándose en 62,5% de las cepas resistentes (5/8). Conclusión: El estudio de la expresión bombas de eflujo por q-PCR podría ser una herramienta diagnóstica útil para la detección temprana de resistencia a azoles en C. albicans.


Subject(s)
Female , Humans , Antifungal Agents/pharmacology , Candida albicans/drug effects , Fluconazole/pharmacology , Voriconazole/pharmacology , Chile , Candida albicans/genetics , Candida albicans/isolation & purification , Drug Resistance, Fungal , Gene Expression Regulation, Fungal , Genes, Fungal/genetics , Real-Time Polymerase Chain Reaction , RNA, Fungal/genetics
SELECTION OF CITATIONS
SEARCH DETAIL